Newsroom

Sorted by: Latest

-

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

BOSTON--(BUSINESS WIRE)--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer...
-

UWM Holdings Corporation to Announce Second Quarter 2026 Financial Results and Host Earnings Q&A

PONTIAC, Mich.--(BUSINESS WIRE)--UWM Holdings Corporation (NYSE:UWMC), the publicly traded indirect parent of United Wholesale Mortgage (UWM), the #1 overall mortgage lender, wholesale and purchase mortgage lender in the U.S., will announce its second quarter 2026 financial results on Thursday, August 6, 2026. A press release with financial highlights will be available on the company’s investor relations website https://investors.uwm.com in the financials section. The company will also host a Q...
-

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver c...
-

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings...
-

ExaGrid lança a versão 8.1

MARLBOROUGH, Massachusetts--(BUSINESS WIRE)--A ExaGrid®, a maior fornecedora independente de armazenamento de backup do mundo, que oferece armazenamento de backup em camadas com a segurança mais abrangente e bloqueio de tempo de retenção com inteligência artificial para recuperação de ransomware, anunciou hoje o lançamento da versão 8.1 do software ExaGrid. A versão mais recente inclui: Suporte ao Cohesity DataProtect Utiliza o protocolo S3. Suporta o Cohesity Cloud Archive Direct. A ExaGrid re...
-

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). NeuroPace has received a communication from FD...
-

九成有限合伙人在信息披露清晰时更倾向于认购使用杠杆的基金

特拉华州威尔明顿--(BUSINESS WIRE)--(美国商业资讯)-- 根据全球领先的商业管理与合规解决方案提供商CSC的最新研究,基金层面的杠杆和流动性工具已从专业的融资技术转变为私募资本的主流基础设施。研究发现,在信息披露清晰的前提下,有限合伙人(LP)对这些工具的使用持越来越开放的态度,但与此同时,普通合伙人(GP)也面临着越来越大的压力,需要证明其背后的运营模式是受控、透明且符合投资者期望的。 CSC¹对北美、欧洲、英国和亚太地区的300位GP和200位LP进行了调查。这份题为《2026年未来私募资本首席财务官(CFO):CFO如何成为运营信任的架构师》(Future Private Capital CFO 2026: How CFOs are becoming the architects of operational trust)的报告探讨了基金融资、流动性管理、报告、外包、网络安全和AI治理如何重塑私募资本CFO的角色。 研究发现,市场已经超越了“是否应该使用基金层面杠杆”的简单争论。相反,LP的关注点正转向杠杆的治理方式、信息披露方式以及在业绩中的反映方式。事实上,...
-

九成有限合夥人在資訊揭露清晰時更傾向於認購使用槓桿的基金

德拉瓦州威爾明頓--(BUSINESS WIRE)--(美國商業資訊)-- 根據全球首屈一指的商業管理與法規遵循解決方案供應商CSC的最新研究,基金層面的槓桿和流動性工具已從專業的募資技術改變為私人資本的主流基礎設施。研究發現,在資訊揭露清晰的前提下,有限合夥人(LP)對這些工具的使用持越來越開放的態度,但與此同時,普通合夥人(GP)也面臨著越來越大的壓力,需要證明其背後的營運模式受控、透明且符合投資人期望。 CSC¹對北美、歐洲、英國和亞太地區的300位GP和200位LP進行了調查。這份標題為《2026年未來私人資本財務長(CFO):CFO如何成為營運信任的架構師》(Future Private Capital CFO 2026: How CFOs are becoming the architects of operational trust)的報告探討了基金募資、流動性管理、報告、外包、資安和AI治理如何重塑私人資本CFO的角色。 研究發現,市場已經超越了「是否應該使用基金層面槓桿」的簡單爭論。相反,LP的關注點正轉向槓桿的治理方式、資訊揭露方式以及在業績中的反映方式。事實上,9...
-

Seacoast Reports Second Quarter 2026 Results

STUART, Fla.--(BUSINESS WIRE)--Seacoast Banking Corporation of Florida ("Seacoast" or the "Company") (NASDAQ: SBCF) today reported unaudited results of operations and other financial information for the second quarter of 2026. Second Quarter 2026 Highlights Net income of $59.5 million, or $0.55 per share, increased 87% from the prior quarter and 39% from the prior year quarter. Adjusted net income1 was $65.8 million, or $0.61 per share. Adjusted pre-tax pre-provision earnings1 increased 4% from...
-

Probe Test Solutions Ltd (PTSL) Drives Industry Consolidation Within the Semiconductor ATE Hardware Sector

GLASGOW, Scotland--(BUSINESS WIRE)--Probe Test Solutions Ltd (PTSL), an established high growth technology company and a world-leader in delivering advanced Automated Test Equipment (“ATE”) test hardware solutions, today announces the recent acquisition of Rucker and Kolls Inc (“R&K”), a U.S. probe card manufacturer. This represents the third acquisition by PTSL, following the earlier acquisition of Probe Technology UK and ThinkMEMS in Dallas, TX.R&K has been a pioneer in providing relia...